Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy

Journal of Infectious Diseases

Volumn 208, Issue 6, 2013, Pages 892-897

  Silva, Erika F ^a   Charreau, Isabelle ^b   Gourmel, Bernard ^a   Mourah, Samia ^a   Kalidi, Issa ^a   Guillon, Brigitte ^b   De Castro, Nathalie ^a   Caron, François ^c   Braun, Josephine ^b   Molina, Jean Michel ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

biomarkers; CRP; D dimer; enfuvirtide; HIV; IL 6; raltegravir; switch

Indexed keywords

C REACTIVE PROTEIN; D DIMER; ENFUVIRTIDE; INTERLEUKIN 6; RALTEGRAVIR;

ADULT; BLOOD CLOTTING; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

BIOMARKERS; CRP; D-DIMER; ENFUVIRTIDE; HIV; IL-6; RALTEGRAVIR; SWITCH;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRROLIDINONES; RNA, VIRAL; SPECIMEN HANDLING; VIRAL LOAD;

EID: 84883225615     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit280     Document Type: Conference Paper

References (15)

1. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203, 1496-1508.
2. Baker JV, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIVAIDS 2010; 5:511-6.
3. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6 and hyaluronic acid before initiation of antiretroviral therapy are associated with increased risk of AIDS and death. J Infect Dis 2011; 203:1637-46.
4. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-95.
5. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease and biomarkers of inflammation, altered coagulation and monocyte activation. Clin Infect Dis 2012; 55:126-36.
6. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-62.
7. Baker JV, Neuhaus J, Duprez D, et al. for the INSIGHT SMART Study Group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56:36-43.
8. McComsey GA, Kitch D, Darr ES, et al. Inflammatory markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir: ACTG A5224s, A5202 substudy. AIDS 2012; 26:1371-85.
9. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1 infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53: 807-16.
10. Gallien S, Braun J, Delaugerre C, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens : 48-week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011; 66:2099-106.
11. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
12. Young B, Vanig T, DeJesus E, et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral naïve HIV-1-infected patients. 48-week results of the SHIELD trial. HIV Clin Trials 2012; 11:206-69.
13. Lake JE, McComsey GA, Hulgan TM, et al. A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDs 2012; 26:532-40.
14. Martinez E, d'Albuquerque PM, Llibre J, et al. the SPIRAL Study Group. Changes of cardiovascular biomarkers in HIV-infected patients switching from ritonavir boosted protease inhibitor to raltegravir. AIDS 2012; 26:2315-26.
15. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7: e1000321.